VITEKTA DIN 02411180
Health Canada record
| Active ingredient(s) | ELVITEGRAVIR 150 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AJ02 ELVITEGRAVIR |
| Original market date | 21-Apr-2015 |
| Current status date | 09-Jan-2017 |
| Source | Health Canada DPD |
Establishment licence of the holder
Gilead Sciences Canada Inc — licence 101221, currently licensed, last inspection rating C (2022-09-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ELVITEGRAVIR
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02449498 | GENVOYA | GILEAD SCIENCES CANADA INC | Tablet | ELVITEGRAVIR 150 MG; COBICISTAT 150 MG; EMTRICITABINE 200 MG; TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE) 10 MG | Marketed |
| 02397137 | STRIBILD | GILEAD SCIENCES CANADA INC | Tablet | ELVITEGRAVIR 150 MG; COBICISTAT 150 MG; EMTRICITABINE 200 MG; TENOFOVIR DISOPROXIL FUMARATE 300 MG | Marketed |
| 02411172 | VITEKTA | GILEAD SCIENCES CANADA INC | Tablet | ELVITEGRAVIR 85 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 14686 | 2013-08-27 | New Drug Submission (NDS) |
International API supply for ELVITEGRAVIR
7 active FDA Drug Master Files.
Request a quote for VITEKTA